8-K: Tenax Therapeutics Secures Global Rights to Levosimendan, Expands Market Potential

Tenax Therapeutics has broadened its license agreement with Orion Corporation, obtaining worldwide rights to develop and commercialize levosimendan-based products, excluding neurological applications.

Summary

• Tenax Therapeutics has amended its license agreement with Orion Corporation, significantly expanding its rights to levosimendan.
• The amendment grants Tenax global rights for oral and subcutaneous levosimendan, previously limited to North America.
• This excludes the treatment of neurological conditions from Tenax's right of first refusal for new levosimendan applications.
• The agreement includes reduced tiered royalties on worldwide net sales, ranging from high single-digit to low-teen percentages.
• A $10 million milestone payment is due to Orion upon FDA approval in the US, and a $5 million milestone payment upon regulatory approval in Japan.
• Tenax also has obligations for up to $45 million in commercialization milestone payments based on cumulative worldwide sales.
• The maximum price per capsule payable by Tenax to Orion for oral levosimendan has been reduced.

Sentiment

Score: 8

Explanation: The document is very positive due to the expansion of global rights, improved royalty rates, and reduced cost of goods. However, the need for additional funding and the loss of rights for neurological applications temper the overall sentiment slightly.

Positives

• Tenax has secured global rights for levosimendan, significantly increasing its market potential.
• The reduced royalty rates will improve profitability.
• The reduced cost of goods will improve profitability.
• The milestone payments are tied to regulatory approvals and sales, aligning incentives.
• The exclusion of neurological indications from the right of first refusal allows Tenax to focus on its core therapeutic areas.

Negatives

• Tenax is obligated to make up to $45 million in commercialization milestone payments.
• The company has lost the right of first refusal for neurological applications of levosimendan.

Risks

• The company is dependent on the successful development and commercialization of levosimendan.
• The company needs to achieve significant sales to trigger the commercialization milestone payments.
• The company is reliant on Orion for the supply of levosimendan.
• The company may face competition from other companies developing treatments for PH-HFpEF.
• The company needs to raise additional funds to pursue its business.

Future Outlook

Tenax is positioned to engage potential global strategic pharmaceutical partners and is pursuing additional IP protection for levosimendan in key countries. The company hopes to provide additional updates in the coming months regarding additional international IP protection.

Management Comments

• Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics, stated that the company has achieved a key corporate objective by expanding its development, IP, and commercial territory rights for levosimendan beyond North America.
• Mr. Giordano also mentioned that the company is now positioned to realize a much larger share of the value of levosimendan, including through the possible establishment of a global strategic alliance.
• Mr. Giordano stated that the efforts to secure global commercial rights and leverage the additional potential IP protection around the world enable the company to build significant shareholder value as they advance levosimendan into Phase 3 testing.

Industry Context

This announcement is significant as it positions Tenax to compete globally in the PH-HFpEF market, a space with high unmet medical need. The expansion of rights allows Tenax to potentially capture a larger share of the market and attract strategic partners.

Comparison to Industry Standards

• The global expansion of rights is a significant move for Tenax, placing it in a similar position to larger pharmaceutical companies with global reach.
• The tiered royalty structure is common in pharmaceutical licensing agreements, but the specific rates are competitive and favorable to Tenax.
• The milestone payments are standard in the industry and are tied to key regulatory and commercial achievements.
• The reduction in the maximum price per capsule is a positive development for Tenax, improving its cost structure.
• The exclusion of neurological indications from the right of first refusal is a strategic decision that allows Tenax to focus on its core therapeutic areas, similar to how other companies focus on specific therapeutic areas.

Stakeholder Impact

• Shareholders will benefit from the increased market potential and improved financial terms.
• Employees may benefit from the company's growth and expansion.
• Patients with PH-HFpEF may benefit from the development of a new treatment option.
• Orion Corporation will receive milestone payments and royalties from the commercialization of levosimendan.

Next Steps

• Tenax will engage potential global strategic pharmaceutical partners.
• Tenax will continue to pursue additional IP protection for levosimendan in key countries.
• Tenax will advance levosimendan into Phase 3 testing.
• Tenax will negotiate a supply agreement with Orion for the commercial supply of oral levosimendan.

Key Dates

Keywords

Levosimendan, Tenax Therapeutics, Orion Corporation, Pulmonary Hypertension, Heart Failure, PH-HFpEF, License Agreement, Global Rights, Milestone Payments, Royalties